

April 20, 2023

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Acadia Pharmaceuticals, Inc. is providing the report for the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program. The required information for the new product being launched is detailed below:

1. Drug Product Description and Launch Information

NDC	Product Name	Date Of Release into Commercial Market
63090066001	Daybue Oral Solution 200 MG/ML, 450 ML, Bottle	3/21/2023

2. Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally

- a. Marketing initiatives include but not limited to the following:
 - i. General advertising and promotion including materials to HCPs, caregivers and websites

Acadia Pharmaceuticals Inc.
Tel. 858-558-2871
Fax. 858-558-2872

12830 El Camino Real, Suite #400
San Diego, CA 92130

www.acadia-pharm.com

- ii. Congresses, speaker programs, business meetings and advisory boards
 - iii. Market research including caregiver experiences, message optimization, diagnosis strategy and patient support service optimization
 - iv. Genetic testing program operations
 - v. Traditional paid media including banner ads for caregivers and HCPs
- b. Acadia does not utilize any one pricing methodology when making pricing decisions. Pricing is based on many key factors, including by not limited to the following:
- i. Significant burden of disease and established efficacy and safety profile
 - ii. High unmet patient need, with DAYBUE being the first approved treatment
 - iii. Rare and well-defined patient population
 - iv. Development pathway to approval
 - v. Market research into comparator products for rare diseases
- 3. Estimated volume of patients who may be prescribed the drug**
- a. 574
- 4. Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval**
- a. FDA priority review granted.
- 5. Date and price of acquisition if the drug was not developed by the manufacturer**
- a. This product was not acquired.

Sincerely,

Mike Rowland

Senior Director, Pricing Contracting and Analytics

Acadia Pharmaceuticals, Inc.